Methamphetamine Causes Degeneration of Dopamine Cell Bodies and Terminals of the Nigrostriatal Pathway Evidenced by Silver Staining

被引:128
作者
Ares-Santos, Sara [1 ,2 ]
Granado, Noelia [1 ,2 ,3 ]
Espadas, Isabel [1 ,2 ]
Martinez-Murillo, Ricardo [1 ]
Moratalla, Rosario [1 ,2 ]
机构
[1] CSIC, Inst Cajal, E-28002 Madrid, Spain
[2] ISCIII, CIBERNED, Madrid, Spain
[3] Univ Complutense Madrid, Fac Med, Madrid, Spain
关键词
amphetamine derivatives; cell death; Parkinson's disease; psychostimulants; neurotoxicity; silver-degeneration stain; SUBSTANTIA-NIGRA; PARKINSONS-DISEASE; STRIATAL DOPAMINE; MOUSE STRIATUM; NEUROTOXICITY; MICE; NEURONS; BRAIN; RECEPTORS; D-1;
D O I
10.1038/npp.2013.307
中图分类号
Q189 [神经科学];
学科分类号
071006 [神经生物学];
摘要
Methamphetamine is a widely abused illicit drug. Recent epidemiological studies showed that methamphetamine increases the risk for developing Parkinson's disease (PD) in agreement with animal studies showing dopaminergic neurotoxicity. We examined the effect of repeated low and medium doses vs single high dose of methamphetamine on degeneration of dopaminergic terminals and cell bodies. Mice were given methamphetamine in one of the following paradigms: three injections of 5 or I 0 mg/kg at 3 h intervals or a single 30 mg/kg injection. The integrity of dopaminergic fibers and cell bodies was assessed at different time points after methamphetamine by tyrosine hydroxylase immunohistochemistry and silver staining. The 3 x 10 protocol yielded the highest loss of striatal dopaminergic terminals, followed by the 3 x 5 and 1 x 30. Some degenerating axons could be followed from the striatum to the substantia nigra pars compacta (SNpc). All. protocols induced similar significant degeneration of dopaminergic neurons in the SNpc, evidenced by amino-cupric-silver-stained dopaminergic neurons. These neurons died by necrosis and apoptosis. Methamphetamine also killed striatal neurons. By using D1-Tmt/D2-GFP BAC transgenic mice, we observed that degenerating striatal neurons were equally distributed between direct and indirect medium spiny neurons. Despite the reduced number of dopaminergic neurons in the SNpc at 30 days after treatment, there was a partial time-dependent recovery of dopamine terminals beginning 3 days after treatment. Locomotor activity and motor coordination were robustly decreased 1-3 days after treatment, but recovered at later times along with dopaminergic terminals. These data provide direct evidence that methamphetamine causes long-lasting loss/degeneration of dopaminergic cell bodies in the SNpc, along with destruction of dopaminergic terminals in the striatum.
引用
收藏
页码:1066 / 1080
页数:15
相关论文
共 67 条
[1]
Albers DS, 1995, J PHARMACOL EXP THER, V275, P1104
[2]
[Anonymous], 2013, WORLD DRUG REP 2013
[3]
[Anonymous], 1981, NEUROANATOMICAL TRAC, DOI DOI 10.1007/978-1-4613-3189-6_4
[4]
The role of dopamine receptors in the neurotoxicity of methamphetamine [J].
Ares-Santos, S. ;
Granado, N. ;
Moratalla, R. .
JOURNAL OF INTERNAL MEDICINE, 2013, 273 (05) :437-453
[5]
Dopamine D1 receptor deletion strongly reduces neurotoxic effects of methamphetamine [J].
Ares-Santos, S. ;
Granado, N. ;
Oliva, I. ;
O'Shea, E. ;
Martin, E. D. ;
Colado, M. I. ;
Moratalla, R. .
NEUROBIOLOGY OF DISEASE, 2012, 45 (02) :810-820
[6]
Ares-Santos S, 2013, BIOLOGICAL RESEARCH ON ADDICTION: COMPREHENSIVE ADDICTIVE BEHAVIORS AND DISORDERS, VOL 2, P579, DOI 10.1016/B978-0-12-398335-0.00057-1
[7]
A COMPARISON OF MODEL-BASED (2D) AND DESIGN-BASED (3D) STEREOLOGICAL METHODS FOR ESTIMATING CELL NUMBER IN THE SUBSTANTIA NIGRA PARS COMPACTA (SNpc) OF THE C57BL/6J MOUSE [J].
Baquet, Z. C. ;
Williams, D. ;
Brody, J. ;
Smeyne, R. J. .
NEUROSCIENCE, 2009, 161 (04) :1082-1090
[8]
Beltramino C A, 1993, NIDA Res Monogr, V136, P101
[9]
BELTRAMINO CA, 1993, NIDA RES MONOGR, V136, P126
[10]
Brain Region-Specific Neurodegenerative Profiles Showing the Relative Importance of Amphetamine Dose, Hyperthermia, Seizures, and the Blood-Brain Barrier [J].
Bowyer, John F. ;
Thomas, Monzy ;
Schmued, Larry C. ;
Ali, Syed E. .
DRUG ADDICTION: RESEARCH FRONTIERS AND TREATMENT ADVANCES, 2008, 1139 :127-139